Double Regional Anesthesia in Video Assisted Thoracoscopy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03852862

Acronym

DRAVATS

Enrollment

112

Registered

2019-02-25

Start date

2019-05-08

Completion date

2020-11-10

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Video Assisted Thoracoscopy

Brief summary

Monocentric, randomized, controlled, single-blind study who's aim is to demonstrate the efficacy of the association of paravertebral block and serratus plane block with paravertebral block alone

Interventions

DRUGSerratus plane block and paravertebral block

Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)

DRUGparavertebral block

Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patient aged 18 to 75 years; * Programmed for unilateral videothoracoscopy for anatomical resection (segmentectomy, lobectomy); * Subject affiliated to a social security scheme; * Subject having signed an informed consent

Exclusion criteria

* Chronic treatment with opiates; * Contraindication to administration of morphine; * Allergy to local anesthetics or contraindications to the use of ropivacaine; * Contraindication to the realization of paravertebral blocks and serratus; * Pregnancy, breastfeeding; * Severe obesity (BMI \> 40 kg/m²); * Renal impairment (GFR \< 30 mL/min) or known severe hepatic impairment; * Difficulties of comprehension preventing the collection of consent and the realization of the study;

Design outcomes

Primary

Measure	Time frame
Number of opioids drug administrated	24 hours postoperatively

Secondary

Measure	Time frame
Length of stay in recovery room	24 hours postoperatively
Total duration of hospitalization	during the 28 days postoperatively

Countries

France

Contacts

PRINCIPAL_INVESTIGATORMarie-Melody DUSSEAUX, MD

University Hospital, Rouen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026